MOLECULAR TESTING FOR HPV

Oncogenic human papilloma virus (HPV) positive head and neck squamous cell carcinoma is potentially curable. Treatment planning requires these cancers to be accurately identified. 

 

Austpath routinely tests these cancers with p16 immunohistochemistry which is a surrogate marker for HPV. Molecular testing for HPV DNA by in situ hybridization is available on request. 

REFERENCES : 

HPV Specific Testing: A Requirement for Oropharyngeal Squamous Cell Carcinoma Patients.

Robinson M, Schache A, Sloan P, Thavaraj S. HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol. 2012 Jul;6 Suppl 1:S83-90. doi: 10.1007/s12105-012-0370-7. Epub 2012 Jul

Human papillomavirus and oropharynx cancer: biology, detection and clinical implications.

Allen CT, Lewis JS Jr, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope. 2010 Sep;120(9):1756-72. doi: 10.1002/lary.20936.

LEGAL

AUSTPATH LABORATORIES

197 Briens Road

Northmead NSW 2152

Telephone : 02 8836 3333